Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-07-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds related to a convertible bond issuance by the company. It details the amount raised, the use of funds, the opening of special accounts, and the supervisory responsibilities of involved parties. The document does not contain financial statements or detailed financial performance data but rather focuses on the regulatory and procedural aspects of fund management. The length is 2493 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP), as it provides an update on the company's fundraising activities and related agreements.
2021-07-05 Chinese
关于取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from a regulatory authority (Guangdong Provincial Drug Administration). It details the product name, registration number, validity period, classification, and intended use. The document also discusses the potential impact on the company and includes a risk warning. There is no financial data, no mention of financial results, no shareholder voting information, no management changes, no capital or financing updates, and no regulatory compliance filings. The document is an official announcement about a regulatory approval related to a product, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or others. It is a regulatory announcement about product registration. Given the options, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories. The document length is short and it is not a report publication announcement or certification. Therefore, classify as RNS with high confidence.
2021-06-29 Chinese
关于董事兼副总经理减持计划实施完毕的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a company director and vice general manager. It details the number of shares reduced, dates, and compliance with relevant laws and regulations. The content focuses on insider share transactions by a company director, including specific share quantities and percentages before and after the reduction. There is no financial report, earnings data, or management discussion. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives.
2021-06-29 Chinese
向不特定对象发行可转换公司债券发行结果公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the issuance results of convertible bonds by 健帆生物科技集团股份有限公司. It details the amount issued, subscription and payment status, underwriting, and registration information. There is no financial statement or detailed financial analysis included, only the results of a capital raising event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. The document length is short (1814 characters), but it contains substantive information about the financing event, not just a notice of report publication. Therefore, the correct classification is CAP.
2021-06-28 Chinese
募集资金管理制度
Regulatory Filings Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, use, supervision, and regulatory compliance related to the company's raised funds. It extensively references laws and regulations governing the use of raised capital, including the establishment of special accounts, usage restrictions, approval processes, and reporting requirements. The document is a policy or procedural manual rather than a financial report or announcement. It does not contain financial statements, earnings data, voting results, or audit opinions. It is not a report publication announcement or a certification. The content fits best under a regulatory or compliance filing category that covers internal rules and governance related to capital management. Given the options, the closest match is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2021-06-28 Chinese
第四届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 19th meeting of the 4th Board of Directors of the company. It details the meeting attendance, the agenda discussed, and the approval of a new 'Fundraising Management System'. There is no financial data or comprehensive report content, but rather a governance-related decision and announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document is short and does not contain financial statements or detailed reports, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive content about board resolutions. Therefore, the classification is MANG with high confidence.
2021-06-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.